查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1797995

2032 年神經調節設備市場預測：按產品類型、適應症、MRI 相容性、生醫材料、最終用戶和地區進行的全球分析

Neuromodulation Devices Market Forecasts to 2032 - Global Analysis By Product Type, Indication, MRI Compatibility, Biomaterial, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球神經調節設備市場預計在 2025 年達到 22 億美元，到 2032 年將達到 120 億美元，預測期內的複合年成長率為 5.0%。

神經調節裝置是一種醫療技術，旨在透過向特定神經或神經部位傳遞定向刺激（例如電脈衝或化學藥劑）來改變神經活動。這些裝置通常用於糾正異常神經訊號，以恢復或使神經系統功能正常化，並緩解慢性疼痛、運動障礙和神經功能障礙等症狀。刺激透過調節神經興奮性和通路，直接影響神經傳遞，進而產生治療效果。

根據美國癲癇基金會和世界衛生組織 (WHO) 的數據，全球約有 5,000 萬人患有癲癇。

慢性神經系統疾病的增加

帕金森氏症、癲癇、阿茲海默症和慢性疼痛症候群等神經系統疾病的盛行率不斷上升，是神經調節設備市場的主要驅動力。人口老化和生活方式相關併發症的增多，推動了對微創、長期治療方案的需求。神經調節設備提供有針對性的、可逆的、可程式設計的治療方案，使其成為一種頗具吸引力的藥物替代方案。神經系統疾病負擔的日益加重，促使醫療保健系統和從業人員採用此類創新治療方法。

神經調節劑高成本

神經調節裝置相關的高昂成本（包括植入、維護和編程）構成了其廣泛應用的重大障礙。高昂的初始投資，加上某些地區的報銷額度有限，限制了其普及，尤其是在中低收入國家。此外，後續觀察、電池更換和設備相關服務進一步增加了長期治療成本。這些經濟限制限制了嚴重患者的應用，並延誤了缺乏足夠保險或政府支持的患者的治療。

神經調節療法的認知度和接受度不斷提高

人們對非藥物疼痛和神經系統治療的認知日益加深，使得患者和醫護人員對神經調節療法的接受度不斷提高。教育宣傳活動、臨床成功案例以及不斷擴展的臨床證據增強了人們對基於設備的治療方法的信心。此外，個人化醫療和精準醫療的轉變也增強了神經調節療法的吸引力。隨著圍繞植入式設備的污名逐漸消退，以及該技術越來越普及，新的患者群體正在進入市場，尤其是在先前缺乏先進神經介入療法服務的地區。

設備相關併發症和副作用的風險

感染疾病、導線移位、硬體故障以及刺激相關副作用等潛在風險仍令人擔憂，威脅市場擴張。這些併發症可能導致設備再次手術或移除，增加患者不適感和治療成本。此外，對手術植入、長期依賴性以及對其他身體系統的潛在干擾的擔憂，也令患者和醫生感到沮喪。負面結果和備受矚目的產品召回也可能影響大眾對神經調節技術的信任。

COVID-19的影響：

由於封鎖措施以及資源向重症監護的重新分配，COVID-19 疫情最初擾亂了擇期神經調節手術。許多患者推遲了手術，導致銷售額和植入數量在短期內下降。然而，疫情後的復甦得益於對慢性病管理的重新關注以及門診治療需求的增加。遠端醫療和遠端設備編程解決方案也已成為寶貴的工具，確保了護理的連續性，並重塑了神經調節領域的服務交付模式。

脊髓刺激設備市場預計將成為預測期內最大的市場

預計脊髓刺激設備細分市場將在預測期內佔據最大市場佔有率，這主要得益於慢性腰腿痛的高發生率。這些裝置廣泛用於治療腰椎手術失敗症候群和複雜性局部疼痛症候群，並已證明其長期療效。閉合迴路系統和無線編程等持續的產品創新正在改善治療效果和患者依從性。此外，主要市場的優惠報銷政策也進一步推動了脊髓刺激設備的大規模應用。

深層腦部刺激器領域預計將在預測期內實現最高複合年成長率

預計深層腦部刺激器領域將在預測期內呈現最高成長率，這得益於對治療帕金森氏症、肌張力不全症和自發性震顫等先進療法的需求不斷成長。精準定位和程式靈活性方面的技術進步正在改善患者的治療效果。此外，在憂鬱症和強迫性精神官能症精神疾病和神經精神疾病應用方面的研究日益增多，也正在擴大深部腦部刺激的應用範圍。隨著臨床適應症的擴展，該領域有望加速全球成長。

比最大的地區

預計亞太地區將在預測期內佔據最大市場佔有率，這得益於神經系統疾病盛行率上升、醫療支出增加以及先進醫療技術日益普及等因素。中國、日本和印度等國家正在大力投資神經病學基礎設施和基於設備的治療。此外，患者意識的增強、私人醫療網路的擴張以及政府在神經復健領域的扶持政策正在推動區域需求。龐大的人口規模和日益加速的都市化進一步鞏固了亞太地區在神經調節設備市場的主導地位。

複合年成長率最高的地區：

預計北美地區在預測期內將實現最高的複合年成長率，這得益於神經病變率的上升、醫療保健支出的增加以及先進醫療技術的普及。中國、日本和印度等國家正在大力投資神經病學基礎設施和基於設備的療法。此外，患者意識的增強、私人醫療網路的擴張以及政府對神經復健的支持也推動了區域需求。龐大的人口和日益加速的都市化進一步鞏固了亞太地區在神經調節設備市場的主導地位。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球神經調節設備市場（依產品類型）

  • 脊髓刺激設備
  • 深層腦部刺激器
  • 薦骨神經刺激器
  • 迷走神經刺激設備
  • 經顱磁刺激儀
  • 其他產品類型

6. 全球神經調節設備市場（按適應症）

  • 慢性疼痛
  • 肌張力不全症
  • 癲癇
  • 自發性震顫
  • 心臟衰竭
  • 重度憂鬱症
  • 帕金森氏症
  • 強迫性精神官能症
  • 膀胱過動症
  • 睡眠呼吸中止症

7. 全球神經調節設備市場：MRI 相容性

  • MRI相容
  • MRI 不相容

8. 全球神經調節設備市場（依生醫材料）

  • 金屬生醫材料
  • 聚合物生醫材料
  • 陶瓷生醫材料

9. 全球神經調節設備市場（依最終用戶）

  • 醫院
  • 神經科診所
  • 家庭醫療保健

第10章全球神經調節設備市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Medtronic
  • Boston Scientific Corporation
  • Stryker
  • Abbott
  • B. Braun Melsungen AG
  • NEVRO CORP.
  • NeuroSigma, Inc
  • NeuroPace, Inc.
  • Soterix Medical Inc
  • Synapse Biomedical Inc
  • ReShape Lifesciences, Inc
  • Bioness Inc.
  • ALEVA NEUROTHERAPEUTICS SA
  • LivaNova PLC
  • Neuronetics
  • Cyberonics, Inc.
  • Neuromod
  • Axonics, Inc.
Product Code: SMRC30365

According to Stratistics MRC, the Global Neuromodulation Devices Market is accounted for $2.2 billion in 2025 and is expected to reach $12.0 billion by 2032 growing at a CAGR of 5.0% during the forecast period. Neuromodulation devices are medical technologies designed to alter nerve activity by delivering targeted stimuli, such as electrical impulses or chemical agents, to specific nerves or neurological sites. These devices modify abnormal nerve signals to restore or normalize nervous system functions, often used to relieve symptoms like chronic pain, movement disorders, or neurological dysfunctions. The stimulation can adjust nerve excitability or pathways, providing therapeutic effects by influencing nerve communication directly.

According to the Epilepsy Foundation of America and World Health Organization (WHO), an estimated 50 million people globally were suffering from epilepsy.

Market Dynamics:

Driver:

Increasing prevalence of chronic neurological diseases

The growing incidence of neurological disorders such as Parkinson's disease, epilepsy, Alzheimer's, and chronic pain syndromes is a key driver for the neuromodulation devices market. With aging populations and lifestyle-related complications on the rise, demand for minimally invasive, long-term therapeutic solutions is increasing. Neuromodulation devices offer targeted, reversible, and programmable therapy, making them attractive alternatives to pharmaceuticals. The rising burden of neurological conditions is pushing healthcare systems and practitioners to adopt these innovative treatment modalities.

Restraint:

High cost of neuromodulation devices

The significant cost associated with neuromodulation devices, including implantation, maintenance, and programming, poses a major barrier to widespread adoption. High initial investment, coupled with limited reimbursement coverage in several regions, restricts access, especially in low- and middle-income countries. Additionally, follow-up visits, battery replacements, and device-related services further inflate long-term treatment costs. These economic limitations discourage adoption in non-critical cases and delay therapy for patients without sufficient insurance or government support.

Opportunity:

Growing awareness and acceptance of neuromodulation therapies

Increased awareness of non-pharmacological pain and neurological treatments has led to rising acceptance of neuromodulation therapies across both patients and healthcare providers. Educational campaigns, clinical success stories, and expanding clinical evidence are building trust in device-based therapies. Furthermore, the shift toward personalized and precision medicine supports neuromodulation's appeal. As stigma around implantable devices decreases and technology becomes more accessible, new patient demographics are entering the market, especially in regions previously underserved by advanced neuro-interventions.

Threat:

Risk of device-associated complications and side effects

Potential risks such as infections, lead migration, hardware malfunction, and stimulation-related side effects remain concerns that threaten the market's expansion. These complications may lead to device revision or explantation, increasing patient discomfort and treatment costs. Moreover, apprehensions about surgical implantation, long-term dependence, and possible interference with other bodily systems can deter both patients and physicians. Negative outcomes or high-profile product recalls could also impact public confidence in neuromodulation technologies.

Covid-19 Impact:

The COVID-19 pandemic initially disrupted elective neuromodulation procedures due to lockdowns and resource reallocation toward critical care. Many patients delayed surgeries, leading to short-term declines in sales and implant volumes. However, post-pandemic recovery has been fueled by a renewed focus on chronic condition management and growing demand for outpatient-based treatments. Telehealth and remote device programming solutions also emerged as valuable tools, ensuring continuity of care and reshaping service delivery models in the neuromodulation sector.

The spinal cord stimulators segment is expected to be the largest during the forecast period

The spinal cord stimulators segment is expected to account for the largest market share during the forecast period propelled by the high prevalence of chronic back and leg pain disorders. These devices are widely used in treating failed back surgery syndrome and complex regional pain syndrome, with proven long-term efficacy. Continuous product innovations, such as closed-loop systems and wireless programming, enhance treatment outcomes and patient compliance. Moreover, favorable reimbursement policies in key markets further support the large-scale adoption of spinal cord stimulators.

The deep brain stimulators segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the deep brain stimulators segment is predicted to witness the highest growth rate, influenced by increasing demand for advanced therapies in managing Parkinson's disease, dystonia, and essential tremor. Technological advancements in targeting precision and programming flexibility are improving patient outcomes. Furthermore, growing research in psychiatric and neuropsychiatric applications, including depression and OCD, is expanding the scope of deep brain stimulation. As clinical indications widen, the segment is positioned for accelerated global growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, fuelled by, rising neurological disorder prevalence, growing healthcare expenditure, and increasing adoption of advanced medical technologies. Countries like China, Japan, and India are investing heavily in neurology infrastructure and device-based therapies. Moreover, growing patient awareness, expanding private healthcare networks, and supportive government initiatives in neurorehabilitation drive regional demand. The large population base and ongoing urbanization further strengthen Asia Pacific's dominance in the neuromodulation devices market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by, rising neurological disorder prevalence, growing healthcare expenditure, and increasing adoption of advanced medical technologies. Countries like China, Japan, and India are investing heavily in neurology infrastructure and device-based therapies. Moreover, growing patient awareness, expanding private healthcare networks, and supportive government initiatives in neurorehabilitation drive regional demand. The large population base and ongoing urbanization further strengthen Asia Pacific's dominance in the neuromodulation devices market.

Key players in the market

Some of the key players in Neuromodulation Devices Market include Medtronic, Boston Scientific Corporation, Stryker, Abbott, B. Braun Melsungen AG, NEVRO CORP., NeuroSigma, Inc, NeuroPace, Inc., Soterix Medical Inc, Synapse Biomedical Inc, ReShape Lifesciences, Inc, Bioness Inc., ALEVA NEUROTHERAPEUTICS SA, LivaNova PLC, Neuronetics, Cyberonics, Inc., Neuromod, and Axonics, Inc.

Key Developments:

In July 2025, Boston Scientific received FDA approval for two new SCS leads-Linear 3-4 and Linear 3-6-for its Precision Plus SCS System, expanding percutaneous lead configuration options in the market.

In April 2025, Abbott introduced a next-generation delivery system for its Proclaim(TM) DRG neurostimulation-the first FDA-approved DRG technology for treating complex regional pain syndrome (CRPS) types 1 & 2-designed to streamline electrode placement to the dorsal root ganglion.

In January 2025, Medtronic achieved CE mark approval for its BrainSense Adaptive Deep Brain Stimulation (aDBS) and Electrode Identifier systems-a significant milestone enabling personalized, sensing-enabled care for Parkinson's patients in Europe.

Product Types Covered:

  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Sacral Nerve Stimulators
  • Vagus Nerve Stimulators
  • Transcranial Magnetic Stimulators
  • Other Product Types

Indications Covered:

  • Chronic Pain
  • Dystonia
  • Epilepsy
  • Essential Tremor
  • Heart Failure
  • Major Depressive Disorder
  • Parkinson's Disease
  • Obsessive-Compulsive Disorder
  • Overactive Bladder
  • Sleep Apnea

MRI Compatibilities Covered:

  • MRI Compatible
  • MRI Non-Compatible

Biomaterials Covered:

  • Metallic Biomaterials
  • Polymeric Biomaterials
  • Ceramic Biomaterials

End Users Covered:

  • Hospital
  • Neurological Clinics
  • Home Healthcare

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neuromodulation Devices Market, By Product Type

  • 5.1 Introduction
  • 5.2 Spinal Cord Stimulators
  • 5.3 Deep Brain Stimulators
  • 5.4 Sacral Nerve Stimulators
  • 5.5 Vagus Nerve Stimulators
  • 5.6 Transcranial Magnetic Stimulators
  • 5.7 Other Product Types

6 Global Neuromodulation Devices Market, By Indication

  • 6.1 Introduction
  • 6.2 Chronic Pain
  • 6.3 Dystonia
  • 6.4 Epilepsy
  • 6.5 Essential Tremor
  • 6.6 Heart Failure
  • 6.7 Major Depressive Disorder
  • 6.8 Parkinson's Disease
  • 6.9 Obsessive-Compulsive Disorder
  • 6.10 Overactive Bladder
  • 6.11 Sleep Apnea

7 Global Neuromodulation Devices Market, By MRI Compatibility

  • 7.1 Introduction
  • 7.2 MRI Compatible
  • 7.3 MRI Non-Compatible

8 Global Neuromodulation Devices Market, By Biomaterial

  • 8.1 Introduction
  • 8.2 Metallic Biomaterials
  • 8.3 Polymeric Biomaterials
  • 8.4 Ceramic Biomaterials

9 Global Neuromodulation Devices Market, By End User

  • 9.1 Introduction
  • 9.2 Hospital
  • 9.3 Neurological Clinics
  • 9.4 Home Healthcare

10 Global Neuromodulation Devices Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Medtronic
  • 12.2 Boston Scientific Corporation
  • 12.3 Stryker
  • 12.4 Abbott
  • 12.5 B. Braun Melsungen AG
  • 12.6 NEVRO CORP.
  • 12.7 NeuroSigma, Inc
  • 12.8 NeuroPace, Inc.
  • 12.9 Soterix Medical Inc
  • 12.10 Synapse Biomedical Inc
  • 12.11 ReShape Lifesciences, Inc
  • 12.12 Bioness Inc.
  • 12.13 ALEVA NEUROTHERAPEUTICS SA
  • 12.14 LivaNova PLC
  • 12.15 Neuronetics
  • 12.16 Cyberonics, Inc.
  • 12.17 Neuromod
  • 12.18 Axonics, Inc.

List of Tables

  • Table 1 Global Neuromodulation Devices Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Neuromodulation Devices Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Neuromodulation Devices Market Outlook, By Spinal Cord Stimulators (2024-2032) ($MN)
  • Table 4 Global Neuromodulation Devices Market Outlook, By Deep Brain Stimulators (2024-2032) ($MN)
  • Table 5 Global Neuromodulation Devices Market Outlook, By Sacral Nerve Stimulators (2024-2032) ($MN)
  • Table 6 Global Neuromodulation Devices Market Outlook, By Vagus Nerve Stimulators (2024-2032) ($MN)
  • Table 7 Global Neuromodulation Devices Market Outlook, By Transcranial Magnetic Stimulators (2024-2032) ($MN)
  • Table 8 Global Neuromodulation Devices Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 9 Global Neuromodulation Devices Market Outlook, By Indication (2024-2032) ($MN)
  • Table 10 Global Neuromodulation Devices Market Outlook, By Chronic Pain (2024-2032) ($MN)
  • Table 11 Global Neuromodulation Devices Market Outlook, By Dystonia (2024-2032) ($MN)
  • Table 12 Global Neuromodulation Devices Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 13 Global Neuromodulation Devices Market Outlook, By Essential Tremor (2024-2032) ($MN)
  • Table 14 Global Neuromodulation Devices Market Outlook, By Heart Failure (2024-2032) ($MN)
  • Table 15 Global Neuromodulation Devices Market Outlook, By Major Depressive Disorder (2024-2032) ($MN)
  • Table 16 Global Neuromodulation Devices Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 17 Global Neuromodulation Devices Market Outlook, By Obsessive-Compulsive Disorder (2024-2032) ($MN)
  • Table 18 Global Neuromodulation Devices Market Outlook, By Overactive Bladder (2024-2032) ($MN)
  • Table 19 Global Neuromodulation Devices Market Outlook, By Sleep Apnea (2024-2032) ($MN)
  • Table 20 Global Neuromodulation Devices Market Outlook, By MRI Compatibility (2024-2032) ($MN)
  • Table 21 Global Neuromodulation Devices Market Outlook, By MRI Compatible (2024-2032) ($MN)
  • Table 22 Global Neuromodulation Devices Market Outlook, By MRI Non-Compatible (2024-2032) ($MN)
  • Table 23 Global Neuromodulation Devices Market Outlook, By Biomaterial (2024-2032) ($MN)
  • Table 24 Global Neuromodulation Devices Market Outlook, By Metallic Biomaterials (2024-2032) ($MN)
  • Table 25 Global Neuromodulation Devices Market Outlook, By Polymeric Biomaterials (2024-2032) ($MN)
  • Table 26 Global Neuromodulation Devices Market Outlook, By Ceramic Biomaterials (2024-2032) ($MN)
  • Table 27 Global Neuromodulation Devices Market Outlook, By End User (2024-2032) ($MN)
  • Table 28 Global Neuromodulation Devices Market Outlook, By Hospital (2024-2032) ($MN)
  • Table 29 Global Neuromodulation Devices Market Outlook, By Neurological Clinics (2024-2032) ($MN)
  • Table 30 Global Neuromodulation Devices Market Outlook, By Home Healthcare (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.